EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Select your location
Local sites
Life Sciences
Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.
Aging populations and chronic disease are putting pressure on health resources around the world just as scientific progress, augmented intelligence and digital data are transforming the traditional health care models. This is causing a power shift with new entrants (often not driven by profit) disrupting the incumbents.
Staying competitive and providing the personalized experience that patients demand require life sciences organizations to find new ways of working. Partnering with others to share data, medicine and resources while anticipating trends and regulatory changes will help ensure sustainability in the increasingly evidence-based, outcomes-focused sector.
We help companies across the biotechnology, pharmaceutical and medical technology fields harness this disruption by forming the right alliances, better allocating resources and building trust with customers.
Our Latest thinking
How biopharma can get the right mix of people and tech for launch success
Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed. Read more.
04 Mar 2025
Daniel Mathews
The Unstoppables: Success stories of the world’s most inspiring entrepreneurs
The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.
12 Nov 2024
Stasia Mitchell
Pulse of the MedTech Industry report 2024
2024 EY MedTech report on dealmaking, financing, and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
07 Oct 2024
Jim Welch
Why licensing deals are a powerful source of growth in life sciences
Innovation is key in Life Sciences. In response to challenges, pharmaceutical companies increasingly turn to external innovation, leveraging licensing deals. Learn more.
03 Oct 2024
Dr. Markus von Minden
How AI is supporting pharmaceutical manufacturing and supply chain
In this episode, listeners will hear how AI is playing an increasingly important role in pharma manufacturing. Learn more.
13 Jun 2024
24m 13s
Beyond Borders: EY Biotechnology Report 2024
New EY biotechnology report with deal, financing and other data, plus insights on AI, GLP-1 drugs, oncology breakthroughs, the VC lens and much more.
03 Jun 2024
What pharma supply chain transformation means for tax
Businesses looking to create visibility and resilience in their supply chains must loop in tax and transfer pricing teams early in the process. Learn more.
15 Mar 2024
Ana Maria Romero
How life sciences can make the right deals in a time of change
Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.
08 Jan 2024
Subin Baral
How will you respond to clinicians sounding the alarm on unsustainable care delivery models?
The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.
16 Oct 2023
Kim Dalla Torre
Why digital supply chain visibility should be a pharma priority
With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.
04 Oct 2023
Derron Stark
How digital is changing the tax strategy for MedTech
As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.
18 Aug 2023
Ana Maria Romero
How Takeda accelerated the financial close process by nearly two weeks
In this case study, learn how leading pharmaceutical company Takeda is creating value for patients through finance innovation and process excellence.
14 Aug 2023
Frederik Schmachtenberg
How early diagnosis can transform health care
Mirxes’ Dr. Zhou Lihan shares his purpose and passion for a more proactive approach to medicine. Learn more.
14 Jun 2023
EY Global
How innovation can unlock the power of data to deliver value-based care
Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Learn more.
20 Mar 2023
Pamela Spence
How life sciences businesses transform the tax and finance function
Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.
07 Mar 2023
EY Global
Why life sciences tax departments need to act now on sustainability
Life sciences organizations should consider tax liabilities and compliance obligations resulting from myriad new sustainability taxes. Learn more.
11 Jan 2023
Rick Fonte
How do you build future supply chains to best serve patient needs?
In the wake of global disruptions, EY research aims to map out the future for supply chain transformation in the pharmaceutical industry. Read more.
18 Jul 2022
Derron Stark
How CDMOs are leading innovation for pharmaceutical partners
Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.
14 Jul 2022
Rubi Gonzalez
What going digital means for Takeda
Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.
01 Jul 2022
Helmut Rattenberger
How to navigate global TP controversy in life sciences — Asia-Pacific and Europe focus
In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in Asia-Pacific and Europe. Learn more.
23 Jun 2022 | your local time
How to navigate global TP controversy in life sciences — US focus
In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in the US. Learn more.
22 Jun 2022 | your local time
How to navigate global transfer pricing controversy in life sciences
Life sciences companies face growing tax authority scrutiny of their transfer pricing practices and must prepare for escalating controversy.
07 Jun 2022
Rick Fonte
How you can create value in an intelligent health ecosystem
The intelligent health ecosystem will provide smarter insights and personalized health care experiences to patients, anytime and anywhere.
26 May 2022
Pamela Spence
How to navigate EU regulations for drug-device combination products
The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.
10 Mar 2022
EY Global
How one entrepreneur seeks to make affordable health care a reality
Celltrion’s JungJin SEO shares his purpose and passion for more accessible health care. Learn more.
01 Mar 2022
EY Global
How data can help redesign the health experience
In this episode of the EY Health Sciences and Wellness Experience Podcast, Pamela Spence discusses the importance of data and how it can help redesign the health experience. Learn more.
21 Feb 2022
16m 52s
How ecosystem participation drives more value for life sciences deals
Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.
10 Jan 2022
Subin Baral
How to account for outcome-based payment arrangements in life sciences
The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.
23 Sep 2021
EY Global
How the future of health care is becoming a reality
Human-centric care will soon become a reality, driven by data and technology.
22 Jun 2021
Pamela Spence
Five trends redefining the health sciences and wellness operating model
As demand from consumers accelerates the adoption of new technologies, we explore how companies can provide a more convenient health experience.
19 May 2021
Pamela Spence
How EY can help
-
The EY Promotional Content Management Services team can provide you with support that will transform your processes and improve your results. Learn more.
Read more -
The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more -
Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more -
The EY Health Outcomes Platform aligns all stakeholders by providing a practical solution to operate value-based contracts at scale. Find out how.
Read more -
Our Field-force Behavioral Benchmarking team can help your business achieve improved commercial performance. Find out how.
Read more -
New EY biotechnology report with deal, financing and other data, plus insights on AI, GLP-1 drugs, oncology breakthroughs, the VC lens and much more.
Read more -
2024 EY MedTech report on dealmaking, financing, and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
Read more
Direct to your inbox
Stay up to date with our Editor's picks newsletter.